Martek fire fallout
This article was originally published in The Tan Sheet
Executive Summary
Fire at supplier DSM's Belvidere, N.J. ARA manufacturing plant will cause an estimated $5 mil. to $10 mil. loss in sales this quarter, Martek estimates in a May 17 statement. The fire shut down ARA production, which could be discontinued at the facility for a period of weeks. The full impact on the firm's revenues "will be determined once the extent of equipment damage is further assessed." Separately, Martek announced the filing of a universal SEC-shelf registration statement May 21 for debt securities, stock and warrants with a value of up to $200 mil...
You may also be interested in...
Glaxo Mother’s goes subcontinental
GlaxoSmithKline launches Mother's Horlicks in India, a powdered drink mix for pregnant and breast-feeding mothers containing Martek's docosahexaenoic acid (DHA), Martek announces June 24. Mother's Horlicks is a "small part" of the Horlicks line, but Martek believes the product "will help set the stage" for expanded food and beverage applications for other products containing DHA. Martek recorded revenues of $41.9 mil. with earnings of $3.4 mil. in its most recent quarter, with results reflecting inefficiencies in the firm's arachidonic acid (ARA) production and a loss of sales due to a fire at a N.J. manufacturing facility (1"The Tan Sheet" May 24, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.